Industry / United Kingdom
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
GSK Looks To Outsourcing For Emerging Market Growth
July 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
The UK's GlaxoSmithKline (GSK) has entered into an agreement with South Africa's Aspen Pharmacare, which it hopes will accelerate its sales in emerging markets. BMI believes that GSK's main motivation for the deal was outsourcing in order to lower costs since GSK will retain responsibility for registration, sales and distribution of the products. BMI expects oncology products to be central to the agreement due to the inclusion of Onco Therapies, Aspen's 50-50 joint venture with India's Strides Arcolab in the